MedTrace Logo

Nicotine Pharmacokinetic Profile of the CHTP 1.1 M

NCT02466412 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2020-05-13

Study results available
· View outcomes & findings →

Summary

The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile of nicotine (rate and amount of nicotine absorbed) after single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M), a potential Modified Risk Tobacco Product, compared to menthol cigarettes (mCC) in healthy smokers.

Conditions

  • Smoking

Interventions

OTHER

CHTP 1.1 M

Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)

OTHER

mCC

Single use of subject's own menthol conventional cigarette (mCC)

Sponsors & Collaborators

  • Philip Morris Products S.A.

    lead INDUSTRY

Principal Investigators

  • Christelle Haziza, PhD · Philip Morris Products S.A.

  • Fumimasa Nobuoka, MD · Ageo Medical Clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
23 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-08-31
Completion
2015-11-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02466412 on ClinicalTrials.gov